ClinicalTrials.gg
RecruitingNCT06342739Updated Apr 2, 2024

Verbal Synchrony, Satisfaction and Decision-making in Face-to-face Consultations

An observational study in Thyroid Nodule, sponsored by European Institute of Oncology. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-02.

Sponsored by European Institute of Oncology · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Started Mar 2022; still recruiting 4 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
60
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Thyroid Nodule with a site in Italy — 6 open to participants now, 6 under way, none of them phase 3. Thyroid Nodule · Italy.

Started
2022
with 1 other
Observational
4 of 11
4 open now
Registered
8th of 11
by date
Lead sponsor
1 of 11
European Institute of Oncology

Among the 11 studies in Thyroid Nodule with a site in Italy, this one is one of 2 that started in 2022, is one of 4 observational ones, and was the 8th registered.

Thyroid Nodule

208 studies on the registry are indexed under Thyroid Nodule; 64 are open to participants now.

Browse Thyroid Nodule studies →

Open to participants now

6 of the 11 studies in Thyroid Nodule with a site in Italy are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 43 Thyroid Nodule studies recruiting now, 33 (77%) set no upper age limit and 5 (12%) stop at 75 or younger; 5 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Thyroid Nodule with a site in Italy, or all of them as a file.
02

Study summary

Eligible participants will be: benign thyroid nodules patients, to be involved in a consultation with their endocrinologist and/or surgeon and/or radiologist, in order to discuss treatment options related to benign thyroid nodules.

Read the detailed description

Eligible participants will be: benign thyroid nodules patients, to be involved in a consultation with their endocrinologist and/or surgeon and/or radiologist, in order to discuss treatment options related to benign thyroid nodules. Endocrinologist and/or surgeon and/or radiologist involved in the consultation will be recruited as well.

Before the scheduled consultation with endocrinologist, surgeon or radiologist, benign thyroid nodules patients will be screened for eligibility by a researcher and a physician from the Interventional Radiology Unit.

If patients meet all the inclusion criteria, they will be contacted by the researcher and proposed to participate. The day of the consultations, researcher will meet participants face to face, they will answer any questions should arise and will ask them to sign the informed consent form.

Benign thyroid nodules patients have a specific clinical pathway, in which they may have consultations with endocrinologists, and/or with surgeon, and/or with radiologists. Patients will be recruited before their first consultation and then, if they are scheduled to have other consultations with other professionals, will be recruited as well for the following consultations.

03

Conditions studied

  • Thyroid Nodule

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with diagnosis of benign thyroid nodule with a scheduled consultation with endocrinologist and/or surgeon and/or radiologist to discuss treatment options related to benign thyroid nodule at European Institute of Oncology

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Specifically, to be eligible for the inclusion in this study, each patient has to fulfill all these criteria:

  • diagnosis of benign thyroid nodule;
  • scheduled consultation with endocrinologist and/or surgeon and/or radiologist to discuss treatment options related to benign thyroid nodule;
  • ≥18 years old at the time of recruitment;
  • proper understanding of Italian language;
  • fluent Italian speaker;
  • able to comply to requested procedures to obtain audio-video recording.

Each professional has to fulfill these criteria:

  • proper understanding of Italian language;
  • fluent Italian speaker;
  • able to comply to requested procedures to obtain audio-video recording.

Exclusion criteria

Exclusion Criteria:

  • Patients with diagnosed mental or neurological disorder that could impair the participation will be excluded from the study.
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
60 participants (estimated)
Patient registry
No

Groups and cohorts

  • Benign thyroid nodules group

    Participants with benign thyroid nodules involved in a consultation with endocrinologist and/or surgeon and/or radiologist, in order to discuss treatment options related to benign thyroid nodules

06

What researchers measure

Primary outcomes

  1. Evaluation of predictive power of verbal synchrony established between patient and physician during the consultation on patients' satisfaction

    The primary endpoint of our research is to test the predictive power of verbal synchrony established between patient and physician during the consultation on patients' satisfaction with tha analysis of audio and video recording file. Variables analyzed from audio recording will be use of words, verbal synchrony, empathic communication; variables analyzed from video recording will be facial emotion expression and facial emotion expression synchrony

    Time frame: 1 month

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2022 (actual). Primary completion is estimated for Dec 2024, 33 months after the start.

Of 38 observational studies under Thyroid Nodule, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 32. This study's planned 33 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2024
First posted
Apr 2, 2024
StartActual
Mar 23, 2022
Primary completionEst.
Dec 31, 2024
CompletionEst.
Dec 31, 2024
Last update
Apr 2, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06342739
Responsible party
Sponsor
First posted
Apr 2, 2024
Start date
Mar 23, 2022
Primary completion
Dec 31, 2024 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
Apr 2, 2024

Study contacts

Gabriella Pravettoni
Contact
gabriella.pravettoni@ieo.it
+390257489731
Gabriella Pravettoni
principal investigator · European Institute of Oncology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion